A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age45+
SponsorGlostrup University Hospital, Copenhagen
About this trial
The aim of this clinical trial is to investigate whether oral semaglutide can be used to treat open-angle glaucoma. The main question it aims to answer is: Does oral semaglutide safely improve inner retinal function in patients with open-angle glaucoma as measured by the photopic negative response of the electroretinogram.
Researchers will compare oral semaglutide to a placebo (a look-alike substance that contains no drug).
Participants will:
* Take semaglutide or a placebo every day for 6 months. * Visit the clinic 5 times in total for tests and interviews: At baseline (the first day they are included in the study), after 1 month, after 2 months, after 3 months, and after 6 months (the last day they are included in the study).
Eligibility criteria
Qualifiers
Ability to read and speak Danish
45 years or older at the time of inclusion
Visual acuity equal to or above 0.5 in the study eye
Diagnosis of POAG with MD ≤ 16 dB with repeatable and reliable (false positive less than 15 %) VF loss measured by standard automated perimetry on at least one eye
Disqualifiers
Diabetes or renal impairment
Medical history of significant eye disease (including ocular trauma) other than glaucoma
Ocular inflammation/infection within three months from inclusion
Intraocular surgery 3 months before inclusion
Trial design
Treatments tested in this trial
- Oral semaglutide
- Placebo
Treatment groups
126 Participants
are divided into 2 treatment groupsSponsors and collaborators
Glostrup University Hospital, Copenhagen
Lead sponsor
Rigshospitalet, Denmark
Sponsor institution
Source ClinicalTrials.gov